Category
70 releases
In this free webinar, learn how small and mid-size organizations can build practical AI governance for clinical trial biometrics. The featured…
New education initiative aims to expand awareness of DBS and empower people with Parkinson's to make informed decisions about their treatment options…
After 25 years moving people for corporations, events and clinical research, MUV becomes a single-focus company: moving the people who bring new…
Updated interim Phase 1 data for oral WEE1 inhibitor APR-1051 to be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium (ENA 2026)…
Gan & Lee Pharmaceuticals (Stock Code: 603087. SH) announced positive topline results from GRADUAL-3, a Phase III clinical study evaluating…
Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments, representing an…
A leading healthcare solutions company with health benefits, pharmacy services and care delivery The leading national retail pharmacy and community…
-- Presented additional 36-week results and 16-week off-drug findings from Part B of the SIGNAL-AA clinical trial of bempikibart in late-breaking…
- $24.7 million in Lumvoa™ (veligrotug-vvze) net product revenue with more than 100 patients on therapy at the end of Q3 2026 -
New study replicates ingredient's bifidogenic effect, stool form outcomes, and tolerability. CARBERRY, MB, Nov. 4, 2026 — MSP Starch Products Inc.,…
Research to be Presented at the 2026 EORTC-NCI-AACR Symposium Links TROP2 Expression to Treatment Response and Explores its Role in Treatment…
Findings build on TJ Biopharma's pioneering work on GM-CSF as a therapeutic target in macrophage- and myeloid cell-driven inflammation Phase 2…
Modern radiotherapy for prostate cancer is as effective as surgery with important advantages in preservation of urinary continence and sexual…
No FDA comments on the study protocol submitted in August 2026, including the primary endpoints and the planned number of approximately 325 patients;…
WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced it received two…
Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended…
SynKIR™-110 demonstrated faster tumor control with approximately 10-fold lower IFNγ and 30-fold lower TNFα and IL-2 production compared to CD28-based…
Earns ESG Risk Rating score of 9.0, ranking among the top 0.5% in the pharmaceuticals industry Advances from 'Low Risk' to 'Negligible Risk,' the…
The acquisition of our newly licensed Hangzhou facility establishes robust local sourcing capabilities to accelerate and support clinical trials…
